XOMA Royalty Corporation announced the resignation of Chief Financial Officer, Thomas Burns, and the appointment of Jeffrey Trigilio as the new CFO.
Thomas Burns played a crucial role in establishing XOMA Royalty as a leading biotech royalty aggregator with a strong financial foundation.
The new CFO, Jeffrey Trigilio, brings extensive experience from various biotech companies and investment banks to drive value for shareholders.
CFO Transition
Thomas Burns stepping down and Jeffrey Trigilio appointed as new CFO.
XOMA's Growth
XOMA Royalty is positioned for future growth with a robust portfolio and multiple commercial assets.
Leadership Strategy
Emphasis on disciplined capital deployment and innovative deal structuring to enhance the royalty portfolio.
- The CFO transition marks a significant change in XOMA Royalty's leadership team, signaling a strategic shift in financial management.
- Jeffrey Trigilio's appointment highlights XOMA's focus on experienced professionals to drive the company's growth and value creation.
XOMA Royalty's future looks promising with a new CFO onboard and a strategic focus on enhancing the royalty portfolio for shareholder value.